SLS SELLAS Life Sciences Group, Inc. - Common Stock
NASDAQ · Biotechnology · 在 SEC EDGAR 上查看 ↗ 收盘 十月 2, 2026 10-K/10-Q 八月 11, 2026SLS 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围
SLS 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图
柱状图粒度会根据所选周期进行调整 — 将鼠标悬停在图表上可查看柱状图的开盘价/最高价/最低价/收盘价。
| 除息日 | 拆股 | 类型 |
|---|---|---|
| 2019年11月8日 | 1-for-50 | 反向 |
| 2018年1月2日 | 1-for-30 | 反向 |
| 2016年11月14日 | 1-for-20 | 反向 |
关于 SELLAS Life Sciences Group, Inc. - Common Stock 公司概况（来自维基百科）
Galena Biopharma, Inc. (originally RXi Pharmaceuticals) was a publicly traded pharmaceutical company based in San Ramon, California. The company was founded in Worcester, Massachusetts. In 2011, it moved to Oregon, and in 2015 moved to San Ramon, California. Mark Schwartz was the company's president and chief executive officer. As of December 29, 2017, the company was acquired by Sellas Life Sciences Group Ltd. through a reverse merger transaction. Galena Biopharma was renamed to Sellas Life Sciences Group, Inc. (Nasdaq: SLS).
History
In November 2006, Argonaut Pharmaceuticals, Inc. changed the name to RXi Pharmaceuticals Corporation. RXi was a subsidiary of CytRx Corp., which provided $15 million in financing in April 2007. RXi was founded in part by Nobel Prize winner Craig Mello. In September 2007, RXi signed a licensing deal with TriLink Biotechnologies, a competitor in the RNA interference (RNAi) field, in which RXi would pay TriLink to use three of TriLink's technologies.
In March 2011, the company announced the planned acquisition of Arizona-based Apthera, Inc. for $7 million. The acquisition included the breast cancer drug NeuVax. In June 2011, NeuVax was approved by the United States Food and Drug Administration to start a stage three clinical trial.
In September 2011, the company separated its cancer therapies division. It was renamed Galena Biopharma Inc and moved to Lake Oswego, Oregon. RXi became a subsidiary of Galena and retained RNAi technologies. RXi Pharmaceuticals remained in Massachusetts as a publicly traded company. In January 2014, Galena bought Mills Pharmaceuticals. In April 2014, the company headquarters moved to Portland.
In November 2011, the company partnered with Genentech to combine drugs from each company for a cancer treatment. Galena is currently studying the combination of NeuVax and Herceptin in phase II trials.
Leadership
In March 2011, president and CEO Noah Beerman were replaced by Mark Ahn, and in August 2014, Ahn resigned and was replaced by Mark Schwartz. On January 31, 2017, Galena announced the resignation of Mark Schwartz effective that day, and reported in the same press release that it would be exploring strategic alternatives to maximize shareholder value going forward.
Stock
RXi went public in March 2008. CytRx retained 49% ownership of RXi's stock and gave shares of RXi to existing shareholders. Trading began on the Nasdaq market on March 12, 2008, under the ticker symbol of RXII. Fidelity Investments invested $8.5 million in the company in May 2008, followed by a $25 million private-equity investment by Yorkville in February 2009. In 2010, RXi received a National Institutes of Health grant of $600,000. By August 2010, the company had 30 employees. In April 2011, RXi raised about $12 million from a stock offering and received $580,000 in grants from the National Institutes of Health. The company reported a loss of $11.5 million loss for 2011.
In November 2012, an anonymous internet report caused Galena stock to decline. The company filed a lawsuit claiming the report was false and attempted to manipulate the stock. In 2014, Galena's involvement in a fraudulent stock promotion scheme was exposed. On February 1, 2014, analyst Matt Gravitt published an article that revealed Galena had paid MissionIR, DreamTeam brand, to promote Galena's stock. Galena's stock fell 20% following this revelation that received a heated response, and was one of the three most read articles in Seeking Alpha's history. Over the next few weeks, more revelations came out and the company admitted their stock promotion relationship and insider selling. Galena then disclosed that the SEC was investigating their relationship with The DreamTeam Group. By March 2014, five lawsuits were filed against Galena and several of its officers alleging that the company used misleading articles to boost stock prices. Motley Fool, discussing the 23% stock price drop during March 2015, noted there was stock dilution from the offering and also that Abstral's sales were below Galena's estimates from late 2013. Discussing the Motley Fool article, Portland Business Journal also noted the ongoing insider-trading lawsuits as a factor in the stock price. A few days later, Zacks Investment Research said Galena could be a "great candidate" to beat its earnings. In response, Galena's CEO said there were many positive aspects to the company, and that the lawsuits weren't a worry as they should get covered under Directors and officers liability insurance. The company moved to San Ramon, California, in the Bay Area in 2015.
Stock promotion scandal
The revelation that Galena was engaging in fraudulent stock promotion without adequate disclosure led to the investigation of other biotech companies who engaged in similar activities. Richard Pearson, an investor who went undercover to investigate the stock promotion firms, wrote an exposé on DreamTeam and its ties to articles about Galena, CytRx, and other companies on media websites. In April 2017, the Securities and Exchange Commission announced enforcement actions against 27 individuals and entities behind various alleged stock promotion schemes. Fraud charges were filed against three public companies, seven stock promotion or communications firms, and two company CEOs; also on this hit list are six individuals and nine writers.
Merger with Sellas Life Sciences
In 2017, Galena Biopharma Inc. announced a merger "with privately-held oncology company Sellas Life Sciences Group Ltd. in an all-stock transaction." The combined company was Sellas Life Science Group. The newly merged companies focused on the development of novel treatments for cancer.
Products
Galena acquired the experimental breast cancer drug NeuVax in 2011 and are currently in phase II trials to combine the drug with Genentech's Herceptin.
In 2013, Galena began selling its first developed drug, an analgesic for cancer pain named Abstral Sublingual.
Anagrelide controlled-released (GALE-401) was approved by the FDA for phase III clinical trials for the treatment of essential thrombocytosis in December 2016.
GALE-301 and GALE-302 are immunotherapies in phase I and II trials for ovarian and breast cancers.
== References ==
来源：维基百科 (英语), CC BY-SA 4.0 · 在维基百科上查看 ↗
10年表现 收入、净利润、利润率和每股收益趋势
估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜？
| 指标 | 5年趋势 | SLS | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| P/E | -55.65年均值 ≈-4.6 | ≈-4.6 | · | · | |
| 市净率 (MRQ) | 17.25年均值 ≈5.3 | ≈5.3 | 4.4 | 估值过高 | |
| Price / Cash Flow (市现率) | -75.05年均值 ≈-5.8 | ≈-5.8 | · | · | |
| Price / Tangible Book (市净率（有形资产）) | 30.95年均值 ≈10.1 | ≈10.1 | · | · |
同行中位数按每项指标的标准化基础计算，可能与本股票显示的TTM/MRQ基础不完全匹配。
盈利能力 毛利率、营业利润率和净利率；股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)
| 指标 | 5年趋势 | SLS | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| ROA | -54.9%5年均值 ≈-160.6% | ≈-160.6% | -40.3% | 弱 | |
| ROE | -55.4%5年均值 ≈-45.6% | ≈-45.6% | -50.3% | 弱 | |
| ROIC | -39.9%5年均值 ≈-177.1% | ≈-177.1% | -39.9% | 持平 |
财务健康 债务、流动性、偿付能力 — 资产负债表强度
| 指标 | 5年趋势 | SLS | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| 流动比率 (MRQ) | 18.85年均值 ≈3.7 | ≈3.7 | 14.8 | 流动性强 | |
| Quick Ratio (速动比率) | 10.25年均值 ≈3.5 | ≈3.5 | 8.7 | 流动性强 |
成长 营收、每股收益 (EPS) 和净利润增长：同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)
基本面数据不足，尚无法计算此比率组。
资本效率 资产周转率、库存周转率、应收账款周转率
| 指标 | 5年趋势 | SLS | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| Revenue / Employee (年营业收入 ÷ 员工人数（报告的 headcount，yfinance）。衍生数据 — 非存储的 SEC-XBRL 概念。) | ≈$0.00 | · | · | · |
价值 · ≈ 5年均值 · 行业中值 · 相对于中值的评判
收益历史 每股收益实际值 vs 预估值，惊喜%，达标率，下次财报日期
| 期间 | 报告 | EPS Actual | EPS 预期 | 惊喜 |
|---|---|---|---|---|
| 2026年6月30日 | 八月 10, 2026 | $-0.05 | $-0.05 | -9.9% |
| 2026年3月31日 | 五月 11, 2026 | $-0.05 | $-0.04 | -23.8% |
| 2025年12月31日 | $-0.05 | $-0.07 | 23.9% | |
| 2025年9月30日 | $-0.06 | $-0.07 | 10.0% | |
| 2025年6月30日 | $-0.07 | $-0.08 | 15.9% | |
| 2025年3月31日 | $-0.07 | $-0.11 | 34.0% | |
| 2024年12月31日 | $-0.08 | $-0.11 | 26.2% |
完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表
损益表
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | $0 | $1M | $8M | $2M | $0 | · | · | · | · | $9M | |
| Cost of Revenue | $0 | $0 | $0 | $100.0K | $200.0K | $0 | · | · | · | · | · | $1M | |
| R&D Expense | · | · | · | · | $16M | $9M | $7M | $9M | $6M | $11M | · | · | |
| SG&A Expense | $12M | $12M | $14M | $13M | $11M | $10M | $10M | $13M | $15M | $5M | · | · | |
| Operating Expenses | $28M | $32M | $38M | $43M | $33M | $19M | $20M | $31M | $23M | $32M | $34M | $44M | |
| Operating Income | $-28M | $-32M | $-38M | $-42M | $-25M | $-17M | $-20M | · | $-23M | $-16M | $-34M | $-44M | |
| Other Non-op | $1M | $632.0K | $529.0K | $649.0K | $4M | $208.0K | $-19M | $-29M | $-24M | $5M | $509.0K | $170.0K | |
| Pretax Income | $-27M | $-31M | $-37M | $-41M | $-21M | $-17M | $-19M | $-29M | $-24M | $-18M | $-39M | $-28M | |
| Income Tax | $0 | $0 | $0 | $0 | $-237.0K | $-17.0K | $-81.0K | $-1M | $300.0K | $1.0K | $365.0K | $0 | |
| Net Income | $-27M | $-31M | $-37M | $-41M | $-21M | $-17M | $-19M | $-28M | $-24M | $-18M | $-64M | $-37M | |
| EPS (Basic) | $-0.25 | $-0.50 | $-1.34 | $-2.13 | $-1.34 | $-2.11 | · | · | · | · | · | · | |
| EPS (Diluted) | $-0.25 | $-0.50 | $-1.34 | $-2.13 | $-1.34 | $-2.11 | · | · | · | · | · | · | |
| Shares (Basic) | 109,051,215 | 61,202,412 | 27,777,111 | 19,395,709 | 15,481,113 | 7,977,104 | · | · | · | · | · | · | |
| Shares (Diluted) | 109,051,215 | 61,202,412 | 27,777,111 | 19,395,709 | 15,481,113 | 7,977,104 | · | · | · | · | · | · | |
| EBITDA | $-28M | $-32M | $-38M | $-42M | $-25M | $-17M | · | · | $-23M | $-32M | · | · |
资产负债表
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $72M | $14M | $3M | $17M | $21M | $35M | $7M | $5M | $2M | $6M | $1M | $24M | |
| Receivables | · | · | · | · | $0 | · | · | · | · | · | · | $2M | |
| Inventory | · | · | · | · | · | · | · | · | · | · | $0 | $655.0K | |
| Prepaid Expense | $3M | $2M | $542.0K | $531.0K | $2M | $395.0K | $557.0K | $387.0K | $337.0K | $332.0K | $1M | $1M | |
| Current Assets | $75M | $16M | $3M | $18M | $23M | $37M | $8M | $6M | $13M | $6M | $54M | $52M | |
| PP&E (Net) | · | · | · | · | · | · | · | · | · | $199.0K | $335.0K | $285.0K | |
| Goodwill | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $6M | $6M | $6M | |
| Total Assets | $78M | $19M | $6M | $21M | $26M | $46M | $17M | $17M | $34M | $6M | $82M | $80M | |
| Accounts Payable | $3M | $4M | $6M | $3M | $2M | $5M | $4M | $4M | $12M | $840.0K | $2M | $2M | |
| Accrued Liabilities | $4M | $5M | $8M | $6M | $3M | $2M | $1M | $2M | $3M | $4M | $5M | $9M | |
| Current Liabilities | $7M | $10M | $14M | $16M | $5M | $12M | $5M | $6M | $25M | $6M | $57M | $27M | |
| Capital Leases | $457.0K | $457.0K | $460.0K | $573.0K | $610.0K | $825.0K | $0 | $0 | · | · | · | · | |
| Deferred Tax | · | · | · | · | $0 | $239.0K | $262.0K | $357.0K | $2M | · | · | · | |
| Total Liabilities | $7M | $10M | $14M | $16M | $6M | $18M | $11M | $12M | $31M | $11M | $69M | $43M | |
| Long-term Debt | · | · | · | · | · | · | · | $0 | $11M | · | $5M | $8M | |
| Total Debt | · | · | · | · | · | · | · | · | $11M | $16M | · | · | |
| Common Stock | $15.0K | $7.0K | $3.0K | $2.0K | $2.0K | $1.0K | $1.0K | $1.0K | $1.0K | $2.0K | $15.0K | $12.0K | |
| Retained Earnings | $-275M | $-248M | $-217M | $-180M | $-139M | $-118M | $-101M | $-82M | $-54M | $-30M | · | · | |
| Treasury Stock | · | · | · | · | · | · | · | · | · | $4M | $4M | $4M | |
| Stockholders' Equity | $71M | $9M | $-8M | $5M | $20M | $28M | $6M | $5M | $2M | $-5M | $-12M | $37M | |
| Liabilities + Equity | $78M | $19M | $6M | $21M | $26M | $46M | $17M | $17M | $34M | $6M | $82M | $80M | |
| Shares Outstanding | 153,103,459 | 73,977,459 | 32,132,890 | 21,005,405 | 15,895,637 | 14,254,554 | 5,080,100 | 440,529 | 5,766,891 | 1,268,489 | 8,095,337 | 109,425,701 |
现金流
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | · | · | $3.0K | $107.0K | $86.0K | |
| Stock-based Comp | $2M | $2M | $2M | $2M | $1M | $578.0K | $573.0K | $395.0K | $3M | $354.0K | $2M | $5M | |
| Deferred Tax | · | · | · | $0 | $-239.0K | $-22.0K | $-95.0K | $-1M | $39.0K | $-41.0K | $365.0K | $0 | |
| Amort. of Intangibles | · | · | · | · | · | · | · | $0 | $2M | · | · | $440.0K | |
| Other Non-cash | · | · | · | · | · | · | · | · | · | $-24M | · | · | |
| Operating Cash Flow | $-28M | $-35M | $-31M | $-24M | $-26M | $-10M | $-18M | $-30M | $-11M | $-12M | $-48M | $-43M | |
| CapEx | · | · | · | · | · | · | · | · | · | $6.0K | $153.0K | $57.0K | |
| Investing Cash Flow | · | $0 | $-6M | $-4M | $0 | · | · | $0 | $12M | $-85.0K | $10M | $-6M | |
| Debt Issued | · | · | · | · | · | · | · | · | · | $2M | $0 | $0 | |
| Net Debt Issued | · | · | · | · | · | · | $0 | · | · | $18M | · | · | |
| Stock Issued | · | $0 | $289.0K | $1M | $9M | $30M | $16M | $22M | $6M | $34M | $47M | $11M | |
| Net Stock Activity | · | $0 | $289.0K | $1M | $9M | $30M | $16M | · | $6M | $34M | · | · | |
| Dividends Paid | · | · | · | · | · | · | $0 | $487.0K | $0 | · | · | · | |
| Financing Cash Flow | $86M | $47M | $22M | $24M | $12M | $38M | $20M | $23M | $6M | $16M | $44M | $24M | |
| Net Change in Cash | $58M | $11M | $-15M | $-4M | $-14M | $28M | $2M | $-7M | $7M | $5M | $6M | $-24M | |
| Taxes Paid | $0 | $0 | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | $-45M | · | · |
盈利能力
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | -4195.0% | -332.8% | -893.8% | · | · | 4986.8% | · | · | · | |
| Net Margin | · | · | · | -4130.1% | -272.4% | -881.9% | -16349.1% | · | 5141.6% | · | · | · | |
| Pretax Margin | · | · | · | -4130.1% | -275.5% | -882.8% | -16417.0% | · | 5086.8% | · | · | · | |
| EBITDA Margin | · | · | · | -4195.0% | -332.8% | -893.8% | · | · | 4986.8% | · | · | · | |
| ROA | -54.9% | -240.8% | -274.9% | -174.9% | -57.2% | -53.5% | -115.1% | · | -118.9% | -31.8% | · | · | |
| ROE | -55.4% | -243.6% | 632.7% | -473.4% | -88.2% | -93.3% | -340.3% | · | 1623.1% | -287.3% | · | · | |
| ROIC | -39.9% | -332.9% | 474.8% | -864.8% | -122.9% | -60.7% | · | · | -178.3% | -72.3% | · | · |
流动性与偿付能力
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.7 | 1.7 | 0.2 | 1.1 | 4.6 | 3.0 | 1.6 | · | 0.5 | 1.2 | · | · | |
| Quick Ratio | 10.2 | 1.5 | 0.2 | 1.1 | 4.3 | 2.9 | 1.4 | · | 0.1 | 0.6 | · | · | |
| Debt / Equity | · | · | · | · | · | · | · | · | 5.3 | 0.6 | · | · | |
| LT Debt / Equity | · | · | · | · | · | · | · | · | 1.3 | · | · | · |
效率
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | 0.0 | 0.0 | 0.2 | 0.1 | 0.0 | · | -0.0 | · | · | · |
每股
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.46 | $0.13 | $-0.25 | $0.23 | $1.28 | $1.96 | $1.20 | · | $0.36 | $1.89 | · | · | |
| Revenue / Share | · | · | $0.00 | $0.05 | $0.49 | · | · | · | · | · | · | · | |
| Cash Flow / Share | $-0.26 | $-0.58 | $-1.13 | $-1.23 | $-1.68 | · | · | · | · | · | · | · | |
| Cash / Share | $0.47 | $0.19 | $0.08 | $0.82 | $1.34 | $2.48 | $1.43 | · | $0.40 | $1.19 | · | · | |
| EPS (TTM) | $-0.25 | $-0.50 | $-1.34 | $-2.13 | $-1.34 | $-2.11 | · | · | · | · | · | · |
增长率
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | · | · | · | -86.8% | 300.0% | · | · | · | · | · | · | · |
估值 (TTM)
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $0 | $0 | $0 | $1M | $8M | $2M | $0 | $10M | $10M | $10M | $10M | $9M | |
| Net Income TTM | $-27M | $-31M | $-37M | $-41M | $-21M | $-17M | $-19M | $-28M | $-24M | $-18M | $-64M | $-37M | |
| Market Cap | $577M | $77M | $34M | $50M | $88M | $83M | $22M | · | $2.25B | $44.20B | · | · | |
| Enterprise Value | · | · | · | · | · | · | · | · | $2.26B | $44.20B | · | · | |
| P/E | -15.1 | -2.1 | -0.8 | -1.1 | -4.1 | -2.8 | · | · | · | · | · | · | |
| P/S | · | · | · | 49.6 | 11.6 | 43.6 | · | · | 223.1 | 4384.0 | · | · | |
| P/B | 8.1 | 8.1 | -4.3 | 10.2 | 4.3 | 3.0 | 3.6 | · | 1086.5 | 1542.5 | · | · | |
| P / Tangible Book | 8.4 | 10.2 | · | 16.9 | 4.8 | 3.2 | · | · | · | · | · | · | |
| P / Cash Flow | -20.3 | -2.2 | -1.1 | -2.1 | -3.4 | -8.0 | -1.2 | · | -204.7 | -984.2 | · | · | |
| P / FCF | · | · | · | · | · | · | · | · | · | -984.0 | · | · | |
| EV / EBITDA | · | · | · | · | · | · | · | · | -98.0 | -1393.3 | · | · | |
| EV / FCF | · | · | · | · | · | · | · | · | · | -984.0 | · | · | |
| EV / Revenue | · | · | · | · | · | · | · | · | 223.9 | 4383.9 | · | · | |
| Dividend Yield | · | · | · | · | · | · | 0.00% | · | 0.00% | · | · | · | |
| Earnings Yield | -6.6% | -48.1% | -126.4% | -90.2% | -24.2% | -36.3% | · | · | · | · | · | · | |
| Payout Ratio | · | · | · | · | · | · | 0.00% | · | · | · | · | · | |
| Annual Payout | · | · | · | · | · | · | $0 | $487.0K | $0 | · | · | · |
损益表
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | · | · | · | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $0 | |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| SG&A Expense | $4M | $4M | $4M | $3M | $3M | $3M | $2M | $3M | $2M | $5M | $3M | $4M | $3M | $4M | $4M | $3M | |
| Operating Expenses | $11M | $9M | $8M | $7M | $7M | $6M | $7M | $7M | $8M | $10M | $8M | $9M | $9M | $11M | $9M | $7M | |
| Operating Income | $-11M | $-9M | $-8M | $-7M | $-7M | $-6M | $-7M | $-7M | $-8M | $-10M | $-8M | $-9M | $-9M | $-11M | $-9M | $-7M | |
| Other Non-op | $1M | $845.0K | $597.0K | $292.0K | $272.0K | $250.0K | $181.0K | $221.0K | $151.0K | $79.0K | $41.0K | $94.0K | $210.0K | $184.0K | $325.0K | $124.0K | |
| Net Income | $-10M | $-8M | $-8M | $-7M | $-7M | $-6M | $-7M | $-7M | $-7M | $-10M | $-8M | $-9M | $-9M | $-11M | $-9M | $-7M | |
| EPS (Basic) | $-0.05 | $-0.05 | $-0.05 | $-0.06 | $-0.07 | $-0.07 | $-0.06 | $-0.10 | $-0.13 | $-0.21 | $-0.23 | $-0.33 | $-0.31 | $-0.47 | $-0.33 | $-0.34 | |
| EPS (Diluted) | $-0.05 | $-0.05 | $-0.05 | $-0.06 | $-0.07 | $-0.07 | $-0.06 | $-0.10 | $-0.13 | $-0.21 | $-0.23 | $-0.33 | $-0.31 | $-0.47 | $-0.33 | $-0.34 | |
| Shares (Basic) | 189,183,620 | 172,481,541 | · | 108,396,260 | 98,558,567 | 87,760,320 | · | 68,254,021 | 57,630,506 | 44,812,996 | · | 28,355,427 | 28,347,920 | 23,547,562 | · | 20,562,351 | |
| Shares (Diluted) | 189,183,620 | 172,481,541 | · | 108,396,260 | 98,558,567 | 87,760,320 | · | 68,254,021 | 57,630,506 | 44,812,996 | · | 28,355,427 | 28,347,920 | 23,547,562 | · | 20,562,351 | |
| EBITDA | $-11M | $-9M | · | $-7M | $-7M | $-6M | · | $-7M | $-8M | $-10M | · | $-9M | $-9M | $-11M | · | $-7M |
资产负债表
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $138M | $107M | $72M | $44M | $25M | $28M | $14M | $21M | $9M | $18M | $3M | $4M | $14M | $24M | $17M | $21M | |
| Prepaid Expense | $4M | $4M | $3M | $5M | $4M | $3M | $2M | $3M | $3M | $3M | $542.0K | $1M | $2M | $2M | $531.0K | $1M | |
| Current Assets | $143M | $111M | $75M | $49M | $29M | $32M | $16M | $24M | $12M | $22M | $3M | $5M | $16M | $26M | $18M | $23M | |
| Goodwill | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Total Assets | $145M | $114M | $78M | $52M | $32M | $35M | $19M | $27M | $15M | $24M | $6M | $8M | $19M | $29M | $21M | $26M | |
| Accounts Payable | $3M | $4M | $3M | $2M | $3M | $4M | $4M | $5M | $6M | $7M | $6M | $4M | $4M | $3M | $3M | $2M | |
| Accrued Liabilities | $4M | $2M | $4M | $3M | $2M | $3M | $5M | $5M | $5M | $7M | $8M | $7M | $6M | $6M | $6M | $5M | |
| Current Liabilities | $8M | $6M | $7M | $6M | $6M | $7M | $10M | $11M | $12M | $14M | $14M | $12M | $13M | $16M | $16M | $13M | |
| Capital Leases | $157.0K | $309.0K | $457.0K | $0 | $157.0K | $309.0K | $457.0K | $0 | $161.0K | $313.0K | $460.0K | $178.0K | $302.0K | $422.0K | $573.0K | $680.0K | |
| Total Liabilities | $8M | $7M | $7M | $6M | $6M | $7M | $10M | $11M | $12M | $15M | $14M | $12M | $14M | $16M | $16M | $13M | |
| Common Stock | $20.0K | $18.0K | $15.0K | $12.0K | $10.0K | $9.0K | $7.0K | $6.0K | $5.0K | $5.0K | $3.0K | $3.0K | $3.0K | $3.0K | $2.0K | $2.0K | |
| Retained Earnings | $-293M | $-283M | $-275M | $-267M | $-261M | $-254M | $-248M | $-241M | $-234M | $-227M | $-217M | $-209M | $-200M | $-191M | $-180M | $-171M | |
| Stockholders' Equity | $138M | $107M | $71M | $46M | $26M | $28M | $9M | $16M | $3M | $10M | $-8M | $-4M | $5M | $13M | $5M | $13M | |
| Liabilities + Equity | $145M | $114M | $78M | $52M | $32M | $35M | $19M | $27M | $15M | $24M | $6M | $8M | $19M | $29M | $21M | $26M | |
| Shares Outstanding | 201,918,874 | 181,332,574 | 153,103,459 | 125,078,525 | 100,367,113 | 90,896,125 | 73,977,459 | 64,381,979 | 57,754,928 | 56,267,670 | 32,132,890 | 28,393,958 | 28,347,920 | 28,347,920 | 21,005,405 | 20,588,247 |
现金流
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $1M | $798.0K | $447.0K | $503.0K | $501.0K | $505.0K | $373.0K | $381.0K | $334.0K | $476.0K | $497.0K | $543.0K | $514.0K | $540.0K | $446.0K | $455.0K | |
| Operating Cash Flow | $-8M | $-9M | $-5M | $-7M | $-7M | $-9M | $-7M | $-8M | $-10M | $-11M | $-5M | $-7M | $-8M | $-12M | $-5M | $-6M | |
| Investing Cash Flow | · | · | · | · | · | · | · | $0 | · | · | $0 | $-3M | · | · | $0 | $0 | |
| Stock Issued | · | · | · | · | · | · | · | $0 | $0 | $0 | $21.0K | $0 | $0 | $268.0K | $929.0K | $69.0K | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | $0 | · | · | · | $268.0K | · | · | |
| Financing Cash Flow | $39M | $44M | $32M | $26M | $4M | $24M | $8.0K | $20M | $414.0K | $27M | $3M | $54.0K | $-29.0K | $19M | $929.0K | $107.0K | |
| Net Change in Cash | $31M | $35M | $27M | $19M | $-3M | $15M | $-7M | $12M | $-9M | $16M | $-1M | $-10M | $-10M | $7M | $-4M | $-6M |
盈利能力
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | · | · | · | · | · | · | -12208.9% | · | · | · | · | · | · | |
| Net Margin | · | · | · | · | · | · | · | · | · | -12108.9% | · | · | · | · | · | · | |
| EBITDA Margin | · | · | · | · | · | · | · | · | · | -12208.9% | · | · | · | · | · | · | |
| ROA | -10.8% | -11.3% | · | -17.4% | -27.8% | -19.6% | · | -41.1% | -44.4% | -35.7% | · | -54.4% | -34.8% | -43.9% | · | -22.0% | |
| ROE | -11.7% | -12.4% | · | -22.1% | -45.4% | -31.1% | · | -117.8% | -192.6% | -83.7% | · | -211.3% | -74.0% | -129.1% | · | -35.8% |
流动性与偿付能力
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 18.8 | 17.2 | · | 8.3 | 4.9 | 4.6 | · | 2.3 | 1.0 | 1.5 | · | 0.4 | 1.2 | 1.7 | · | 1.8 | |
| Quick Ratio | 18.3 | 16.6 | · | 7.5 | 4.2 | 4.1 | · | 2.0 | 0.8 | 1.3 | · | 0.3 | 1.0 | 1.5 | · | 1.7 |
效率
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | · | · | · | · | · | · | · | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 |
每股
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.68 | $0.59 | · | $0.36 | $0.26 | $0.31 | · | $0.25 | $0.05 | $0.17 | · | $-0.13 | $0.17 | $0.46 | · | $0.61 | |
| Revenue / Share | · | · | · | · | · | · | · | · | · | $0.00 | · | $0.00 | $0.00 | $0.00 | · | $0.00 | |
| Cash Flow / Share | · | $-0.05 | · | · | · | $-0.10 | · | · | · | $-0.24 | · | · | · | $-0.52 | · | · | |
| Cash / Share | $0.69 | $0.59 | · | $0.35 | $0.25 | $0.31 | · | $0.33 | $0.16 | $0.33 | · | $0.14 | $0.49 | $0.84 | · | $1.04 | |
| EPS (TTM) | $-0.21 | $-0.23 | · | $-0.26 | $-0.30 | $-0.36 | · | $-0.67 | $-0.90 | $-1.08 | · | $-1.44 | $-1.45 | $-1.55 | · | $-2.23 |
估值 (TTM)
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $0 | $0 | · | $0 | $0 | $0 | · | $0 | $0 | $0 | · | $0 | $0 | $0 | · | $1M | |
| Net Income TTM | $-32M | $-29M | · | $-26M | $-26M | $-27M | · | $-32M | $-34M | $-36M | · | $-38M | $-36M | $-36M | · | $-39M | |
| Market Cap | $2.98B | $767M | · | $201M | $220M | $98M | · | $80M | $69M | $57M | · | $47M | $45M | $41M | · | $42M | |
| P/E | -70.3 | -18.4 | · | -6.2 | -7.3 | -3.0 | · | -1.9 | -1.3 | -0.9 | · | -1.1 | -1.1 | -0.9 | · | -0.9 | |
| P/S | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | 41.6 | |
| P/B | 21.7 | 7.1 | · | 4.4 | 8.4 | 3.5 | · | 5.1 | 23.6 | 5.9 | · | -12.2 | 9.2 | 3.1 | · | 3.3 | |
| P / Tangible Book | 22.0 | 7.3 | · | 4.6 | 9.1 | 3.8 | · | 5.8 | 68.8 | 7.3 | · | · | 15.2 | 3.6 | · | 3.9 | |
| P / Cash Flow | · | -86.7 | · | · | · | -10.8 | · | · | · | -5.3 | · | · | · | -3.3 | · | · | |
| Earnings Yield | -1.4% | -5.4% | · | -16.2% | -13.7% | -33.3% | · | -53.6% | -75.6% | -106.9% | · | -87.8% | -92.4% | -108.4% | · | -110.4% |
最近期在左侧 · 空值显示为 ·
财务报表 损益表、资产负债表、现金流量表 — 年度，近5年
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 收入 | · | · | $0 | $1M | $8M |
| 营业利润率 % | · | · | · | -4195.0% | -332.8% |
| 净收入 | $-27M | $-31M | $-37M | $-41M | $-21M |
| 稀释后每股收益 (EPS) | $-0.25 | $-0.50 | $-1.34 | $-2.13 | $-1.34 |
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 流动比率 | 10.7 | 1.7 | 0.2 | 1.1 | 4.6 |
| 速动比率 | 10.2 | 1.5 | 0.2 | 1.1 | 4.3 |
基本面数据不足，尚无法生成此报表。
机构持有人 (13F) 234 家申报者 · $1.5B 总计 · 截至 2026年9月30日
在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸；单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存，而非方向性判断。
| 新仓位 | 已退出持仓 | 增加 | 减少 | 净股数变动 |
|---|---|---|---|---|
| 85 (+18 与上一季度对比) | 19 (+4 与上一季度对比) | 84 (+25 与上一季度对比) | 31 (+8 与上一季度对比) | +33.3M |
与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天，外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过，优先显示最近一个已完整报告的季度对。
| 机构 | 价值 | 股份 | % 已追踪的13F | 类型 |
|---|---|---|---|---|
| BlackRock, Inc. | $222437657 | 15070302 | 14.45% | 股份 |
| STATE STREET CORP | $191829196 | 12996558 | 12.47% | 股份 |
| VANGUARD CAPITAL MANAGEMENT LLC | $121417310 | 8226105 | 7.89% | 股份 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $105640272 | 7157200 | 6.86% | 买入期权 |
| GEODE CAPITAL MANAGEMENT, LLC | $72107010 | 4884175 | 4.69% | 股份 |
| Anson Funds Management LP | $66420000 | 4500000 | 4.32% | 股份 |
| CITADEL ADVISORS LLC | $64157292 | 4346700 | 4.17% | 买入期权 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $61832592 | 4189200 | 4.02% | 卖出期权 |
| CITADEL ADVISORS LLC | $33333984 | 2258400 | 2.17% | 卖出期权 |
| VANGUARD GROUP INC | $31922098 | 8467400 | 2.07% | 股份 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $31897821 | 2161099 | 2.07% | 股份 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $30266812 | 2050597 | 1.97% | 股份 |
| JONES FINANCIAL COMPANIES LLLP | $28553511 | 2304561 | 1.86% | 股份 |
| Anson Funds Management LP | $27245484 | 1845900 | 1.77% | 卖出期权 |
| NORTHERN TRUST CORP | $23910138 | 1619928 | 1.55% | 股份 |
| PERCEPTIVE ADVISORS LLC | $22140000 | 1500000 | 1.44% | 卖出期权 |
| VANGUARD FIDUCIARY TRUST CO | $19707050 | 1335166 | 1.28% | 股份 |
| UBS Group AG | $18490693 | 1252757 | 1.20% | 股份 |
| MORGAN STANLEY | $18247211 | 1236261 | 1.19% | 股份 |
| Sio Capital Management, LLC | $18165132 | 1230700 | 1.18% | 卖出期权 |
| BNP PARIBAS FINANCIAL MARKETS | $15823045 | 1072022 | 1.03% | 股份 |
| BNP PARIBAS FINANCIAL MARKETS | $15424200 | 10450 | 1.00% | 卖出期权 |
| MILLENNIUM MANAGEMENT LLC | $13372560 | 906000 | 0.87% | 卖出期权 |
| BARCLAYS PLC | $11831616 | 801600 | 0.77% | 卖出期权 |
| Anson Funds Management LP | $11808000 | 800000 | 0.77% | 买入期权 |
| BANK OF AMERICA CORP /DE/ | $11630128 | 787949 | 0.76% | 股份 |
| JANE STREET GROUP, LLC | $11058192 | 749200 | 0.72% | 买入期权 |
| WELLINGTON MANAGEMENT GROUP LLP | $8816282 | 597309 | 0.57% | 股份 |
| GOLDMAN SACHS GROUP INC | $8635117 | 585035 | 0.56% | 股份 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $8339518 | 565008 | 0.54% | 股份 |
| Bank of New York Mellon Corp | $7823173 | 530025 | 0.51% | 股份 |
| JANE STREET GROUP, LLC | $7504412 | 508429 | 0.49% | 股份 |
| Balyasny Asset Management L.P. | $7380000 | 500000 | 0.48% | 卖出期权 |
| LMR Partners LLP | $6642000 | 450000 | 0.43% | 卖出期权 |
| NOMURA HOLDINGS INC | $6273000 | 425000 | 0.41% | 买入期权 |
| Nuveen, LLC | $6180440 | 418729 | 0.40% | 股份 |
| DIADEMA PARTNERS LP | $5904000 | 400000 | 0.38% | 买入期权 |
| Invesco Ltd. | $5540049 | 375342 | 0.36% | 股份 |
| Swiss National Bank | $5319504 | 360400 | 0.35% | 股份 |
| XTX Topco Ltd | $5300168 | 359090 | 0.34% | 股份 |
| Ikarian Capital, LLC | $5235372 | 354700 | 0.34% | 卖出期权 |
| WELLS FARGO & COMPANY/MN | $4853368 | 328819 | 0.32% | 股份 |
| CITIGROUP INC | $4820483 | 326591 | 0.31% | 股份 |
| RENAISSANCE TECHNOLOGIES LLC | $4580973 | 310364 | 0.30% | 股份 |
| DAGCO, INC. | $4351740 | 1028780 | 0.28% | 股份 |
| Everhart Financial Group, Inc. | $4251146 | 288018 | 0.28% | 股份 |
| Rafferty Asset Management, LLC | $3540806 | 239892 | 0.23% | 股份 |
| RHUMBLINE ADVISERS | $3400726 | 230402 | 0.22% | 股份 |
| Walleye Capital LLC | $3377088 | 228800 | 0.22% | 卖出期权 |
| TUDOR INVESTMENT CORP ET AL | $3087792 | 209200 | 0.20% | 卖出期权 |
激进投资者及 5%+ 股东 2 持仓
提交了 SEC Schedule 13D 的投资者 — 持有超过 5% 的受益所有权，意图影响发行人（激进股东持股、董事会活动、并购）。每一行显示该申报人持仓的最新已知状态。
| 申报人 | 已申报 | 持股 | 状态 | 目的 | 申报 |
|---|---|---|---|---|---|
| Equilibria Capital Management Limited (2), EQC Private Markets SAC Fund II Ltd — EQC Biotech Sely S Fund (2), EQC Private Markets SAC Fund Ltd — EQC Biotech Sely I Fund (2), EQC Private Markets SAC Fund Ltd — EQC Biotech Sely II Fund (2), EQC Private Markets II SAC Fund Ltd — EQC Biotech Sely III Fund (2), Varibobi Financial Holdings Ltd. (2), Daniel Tafur (2), Fabio López (2) ×4 申报 | 2018年10月10日 | · | 初始申报 | · | SEC |
| Angelos M. Stergiou, M.D., Sc.D. h.c. | 2018年1月8日 | · | 初始申报 | 并购/出售 | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
公司内部人士 43 位内幕人士 · 17 位高管 · 9 位董事
| 内部人士 | 角色 | 上次活动 | 持股数量 | 买入 12个月 | 卖出 12个月 | 净额 12个月 |
|---|---|---|---|---|---|---|
| Andelos M. Stergiou | President and CEO | 2026年6月16日 A | 1759183 | 0 | 0 | $0 |
| Mark W. Schwartz | President & CEO | 2016年7月1日 J | 439978 | 0 | 0 | $0 |
| Noah D Beerman | CEO and President | 2011年3月15日 A | 92994 | 0 | 0 | $0 |
| John Thomas Burns | CFO | 2026年1月7日 A | 554327 | 0 | 0 | $0 |
| Gene Mack | CFO and Treasurer | 2018年4月20日 A | · | 0 | 0 | $0 |
| Robert Eugene Kennedy | Vice President and CFO | 2011年4月13日 A | 379294 | 0 | 0 | $0 |
| Stephen J. Dipalma | CFO, EVP, Secretary | 2009年1月15日 A | · | 0 | 0 | $0 |
| Dragan Cicic | SVP, Chief Development Officer | 2026年1月7日 A | 557805 | 0 | 0 | $0 |
| Robert Francomano | Chief Commercial Officer | 2024年1月22日 A | 40918 | 0 | 0 | $0 |
| Barbara A Wood | EVP, Gen. Counsel, Corp. Sec. | 2024年1月22日 A | 117225 | 0 | 0 | $0 |
| Nicholas J. Sarlis | Chief Medical Officer and SVP | 2019年3月14日 A | · | 0 | 0 | $0 |
| Gregory M Torre | CRO and SVP | 2018年3月13日 A | · | 0 | 0 | $0 |
| Kwang Lee | Principal Accounting Officer | 2011年12月7日 P | 5000 | 0 | 0 | $0 |
| Amy B Tata | Principlw Acctg Officer & Cont | 2011年3月15日 A | 14065 | 0 | 0 | $0 |
| Ramani Varanasi | VP Business Development | 2011年3月15日 A | 41083 | 0 | 0 | $0 |
| Konstantinos Andrikopoulos | VP, Legal | 2010年4月15日 A | 5750 | 0 | 0 | $0 |
| Dmitry Samarsky | VP, Technology Development | 2010年3月31日 S | 0 | 0 | 0 | $0 |
| Katherine Bach Kalin | 董事 | 2026年1月7日 A | 154400 | 1 | 0 | $100806 |
| John Varian | 董事 | 2026年1月7日 A | 72900 | 0 | 0 | $0 |
| Jane Wasman | 董事 | 2026年1月7日 A | 92900 | 0 | 0 | $0 |
| David A Scheinberg | 董事 | 2026年1月7日 A | 73082 | 0 | 0 | $0 |
| Robert L Van Nostrand | 董事 | 2026年1月7日 A | 82900 | 0 | 0 | $0 |
| Stephen F Ghiglieri | 董事 | 2019年3月14日 A | · | 0 | 0 | $0 |
| Fabio Lopez | 董事 | 2018年6月12日 A | · | 0 | 0 | $0 |
| Irving M. Einhorn | · | 2017年10月10日 A | 34690 | 0 | 0 | $0 |
| William Ashton | · | 2017年10月10日 A | 38154 | 0 | 0 | $0 |
| Richard Chin | · | 2017年10月10日 A | 31339 | 0 | 0 | $0 |
| Rudolph Nisi | · | 2017年10月10日 A | 42918 | 0 | 0 | $0 |
| Sanford Hillsberg | · | 2017年10月10日 A | 56950 | 0 | 0 | $0 |
| Mary Ann Gray | · | 2017年10月10日 A | 39167 | 0 | 0 | $0 |
| Stephen S Galliker | · | 2017年10月10日 A | 36039 | 0 | 0 | $0 |
| Thomas J Knapp | · | 2017年2月6日 A | · | 0 | 0 | $0 |
| Bijan Nejadnik | · | 2017年1月17日 A | 8503 | 0 | 0 | $0 |
| Ryan Dunlap | · | 2016年6月1日 M | 18702 | 0 | 0 | $0 |
| Steven A Kriegsman | · | 2015年6月19日 A | 5000 | 0 | 0 | $0 |
| Margaret Kivinski | · | 2015年1月16日 A | · | 0 | 0 | $0 |
| Brian L Hamilton | · | 2014年6月30日 J | 2461 | 0 | 0 | $0 |
| Mark J Ahn | · | 2014年6月30日 A | 116225 | 0 | 0 | $0 |
| Rosemary Mazanet | · | 2013年1月29日 A | · | 0 | 0 | $0 |
| Anastasia Khvorova | · | 2011年9月24日 A | 137482 | 0 | 0 | $0 |
| Pamela Pavco | · | 2011年9月24日 A | 44940 | 0 | 0 | $0 |
| CYTRX CORP | · | 2010年12月29日 S | 0 | 0 | 0 | $0 |
| Tod Woolf | · | 2009年1月15日 A | · | 0 | 0 | $0 |
来自SEC表格3/4/5申报的内部人士；净额=仅公开市场买卖
ETF持仓 由 25 只交易所交易基金持有
权重仅反映直接股权持仓（N-PORT）；杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。
| 基金 | 权重 | 单位 | 截至 | 来源 |
|---|---|---|---|---|
| BBC · ETFis Series Trust I | 0.86% | 39695 NS | 2026年7月31日 | N-PORT |
| IWC · iShares Trust | 0.60% | 640712 SH | 2026年9月11日 | 每日 |
| LABU · Direxion Shares ETF Trust | 0.59% | 293250 NS | 2026年7月31日 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0.23% | 316525 SH | 2026年8月19日 | 每日 |
| ICOP · iShares Trust | 0.21% | 131527 SH | 2026年9月11日 | 每日 |
| IWO · iShares Trust | 0.17% | 1775566 SH | 2026年9月11日 | 每日 |
| PWS · Pacer Funds Trust | 0.17% | 4006 NS | 2026年7月31日 | N-PORT |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.16% | 202339 SH | 2026年8月19日 | 每日 |
| IWM · iShares Trust | 0.08% | 4838243 SH | 2026年9月11日 | 每日 |
| ISCG · iShares Trust | 0.08% | 57697 SH | 2026年9月11日 | 每日 |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.08% | 1086285 SH | 2026年8月19日 | 每日 |
| RSSL · Global X Funds | 0.06% | 90355 NS | 2026年7月31日 | N-PORT |
| ESML · iShares Trust | 0.05% | 105699 SH | 2026年9月11日 | 每日 |
| PICK · iShares, Inc. | 0.05% | 147515 SH | 2026年9月11日 | 每日 |
| VHT · VANGUARD WORLD FUND | 0.04% | 540244 SH | 2026年8月19日 | 每日 |
| ISCF · iShares Trust | 0.04% | 30200 SH | 2026年9月11日 | 每日 |
| VXF · VANGUARD INDEX FUNDS | 0.03% | 2134285 SH | 2026年8月19日 | 每日 |
| WSML · iShares Trust | 0.03% | 17066 SH | 2026年9月11日 | 每日 |
| FHLC · FIDELITY COVINGTON TRUST | 0.03% | 85332 NS | 2026年7月31日 | N-PORT |
| ITOT · iShares Trust | 0.00% | 273788 SH | 2026年9月11日 | 每日 |
| IWV · iShares Trust | 0.00% | 44399 SH | 2026年9月11日 | 每日 |
| IXUS · iShares Trust | 0.00% | 98316 SH | 2026年9月11日 | 每日 |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 5908560 SH | 2026年8月19日 | 每日 |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 15706 SH | 2026年8月19日 | 每日 |
| ISCB · iShares Trust | · | 8283 SH | 2026年9月11日 | 每日 |
SLS 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间
12个月价格目标
2 位分析师 · 2026-10-02平均目标 $32.50 +176.8%
同行比较（GICS 子行业） 关键指标与行业同行对比
财年依据，价格截至各公司上一个财年末收盘价。
| 股票代码 | 市值 | P/E | 营收同比增长 | 净利润率 | ROE | 毛利率 |
|---|---|---|---|---|---|---|
| SLS | $577M | -15.1 | · | · | -55.4% | · |
| BEAM | $2.82B | -34.2 | 120.0% | -57.2% | -7.0% | · |
| CLDX | $1.81B | -7.0 | -78.0% | -16748.0% | -43.8% | · |
| IRON | $3.01B | -13.2 | · | · | -31.3% | · |
| NRIX | $1.80B | -5.8 | 53.9% | -314.9% | -53.6% | · |
| IMNM | $2.43B | -8.8 | -23.2% | -3060.0% | -47.0% | · |
| VRDN | $3.17B | -7.7 | 23359.9% | -483.6% | -55.4% | · |
| RXRX | $2.16B | -2.8 | 26.9% | -863.4% | -62.9% | · |
| VERA | · | -10.9 | · | · | -55.9% | · |
| ADMA | $4.34B | 30.4 | 19.6% | 28.8% | 33.6% | 57.4% |
最新新闻 提及该公司的近期头条新闻
我的指标 您的个人关注列表 — 来自完整基本面的选定行
选择对您重要的指标 — 点击上方完整基本面中任意行的 + 号。
您的选择已保存，并会跟随您浏览所有股票。